共查询到20条相似文献,搜索用时 15 毫秒
1.
Fletcher O Johnson N Palles C dos Santos Silva I McCormack V Whittaker J Ashworth A Peto J 《Journal of the National Cancer Institute》2006,98(14):1014-1018
STK15 may be a low-penetrance breast cancer susceptibility gene, and several reports suggest that women who are homozygous for the polymorphic variant F31I have an increased risk of breast cancer. To evaluate this potential breast cancer allele, we genotyped 507 patients with two primary breast cancers and 875 population-based control subjects for the STK15 F31I polymorphism. All statistical tests were two-sided. The Ile/Ile homozygous genotype was not associated with an increased risk in white women of British descent. The odds ratio for developing two primary breast cancers) in Ile/Ile homozygotes was 0.63 (95% confidence interval [CI] = 0.34 to 1.13), which corresponds to an odds ratio of 0.79 (95% CI = 0.58 to 1.06) for a first primary breast cancer. A meta-analysis of this study and other published studies showed statistically significant heterogeneity in the odds ratio estimates (P<.001). This heterogeneity could reflect either population-specific linkage disequilibrium with a functional variant or artifacts such as population stratification or publication bias. 相似文献
2.
Li-Xin Qiu Jian Zhang Xiao-Dong Zhu Chun-Lei Zheng Si Sun Zhong-Hua Wang Xin-Min Zhao Jia-Lei Wang Lei-Ping Wang Hui Yu Kai Xue Xi-Chun Hu 《Breast cancer research and treatment》2010,124(2):475-479
Published data on the association between p21 Ser31Arg polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between the p21 Ser31Arg polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (Ser/Arg vs. Ser/Ser, Arg/Arg vs. Ser/Ser), dominant model (Arg/Arg + Ser/Arg vs. Ser/Ser), and recessive model (Arg/Arg vs. Ser/Arg + Ser/Ser). A total of 21 studies including 22,109 cases and 29,127 controls were involved in this meta-analysis. Overall, no significant associations were found between p21 Ser31Arg polymorphism and breast cancer risk when all studies pooled into the meta-analysis. In the subgroup analysis by ethnicity, significantly increased risk was found for Caucasians (Arg/Arg vs. Ser/Ser: OR 1.496, 95% CI 1.164–1.924; and recessive model: OR 1.492, 95% CI 1.161–1.919). When stratified by study design, statistically significantly elevated risk was found for population-based studies (Ser/Arg vs. Ser/Ser: OR 1.085, 95% CI 1.019–1.156). In conclusion, this meta-analysis suggests that the p21 Ser31Arg polymorphism may be associated with breast cancer development in Caucasian. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
3.
Haiming Sun Jing Bai Feng Chen Yan Jin Yang Yu Lianhong Jin Songbin Fu 《Breast cancer research and treatment》2011,125(1):157-161
Several studies have investigated the associations between RAD51 G135C polymorphism and the susceptibility to breast cancer,
but results have been inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was
performed. A total of 17 case control studies, including 12,153 cases and 10,245 controls, were selected. Overall, significant
decreased risk was found for the additive model (OR = 0.995, 95% CI = 0.991–0.998) and dominant model (OR = 0.994, 95% CI = 0.991–0.998).
In the subgroup analysis by ethnicity, statistically significantly decreased risk was found in Asians (additive model: OR = 0.977,
95% CI = 0.954–1.000 and dominant model: OR = 0.981, 95% CI = 0.963–1.000). In conclusion, this meta-analysis suggests that
the RAD51 G135C polymorphism is a low-penetrant risk factor for developing breast cancer. 相似文献
4.
Li-Xin Qiu Lei Yao Chen Mao Bo Chen Ping Zhan Kai Xue Jian Zhang Hui Yuan Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):563-567
Published data on the association between TGFB1 L10P polymorphism and breast cancer risk are inconclusive. In order to derive
a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the
strength of association between them. A total of 30 studies including 20,401 cases and 27,416 controls were involved in this
meta-analysis. Overall, significantly elevated breast cancer risk was associated with TGFB1 10P allele when all studies were
pooled into the meta-analysis (LP vs. LL: OR = 1.046, 95% CI = 1.003–1.090; dominant model: OR = 1.052, 95% CI = 1.012–1.095).
In the subgroup analysis by ethnicity, statistically significantly elevated risk was found in Caucasians (dominant model:
OR = 1.045, 95% CI = 1.001–1.091). When stratified by study design, statistically significantly elevated risk was found based
on population-based studies (dominant model: OR = 1.076, 95% CI = 1.019–1.136). In conclusion, this meta-analysis suggests
that the TGFB1 10P allele may be a low-penetrant risk factor for developing breast cancer. However, large sample and representative
population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
5.
Egan KM Newcomb PA Ambrosone CB Trentham-Dietz A Titus-Ernstoff L Hampton JM Kimura MT Nagase H 《Carcinogenesis》2004,25(11):2149-2153
STK15 is considered a potential cancer susceptibility gene owing to its functions in normal cell mitosis. Two common coding region polymorphisms in the gene (F31I and V57I) may affect ubiquitin-dependent degradation and thus the half-life of the encoded protein. There are limited data on the relevance of these polymorphisms to population cancer rates. To examine whether functional variation in STK15 may affect breast cancer risk, we genotyped a large series of incident breast cancer cases (n = 941) and age-matched population controls (n = 830) for the F31I and V57I polymorphisms. Individually, neither the F31I polymorphism [odds ratio (OR) 1.54; 95% confidence interval (CI) 0.96-2.47, comparing 31I with 31F homozygotes] nor the V57I polymorphism (OR 0.92; 95% CI 0.50-1.71, comparing 57I with 57V homozygotes) was significantly associated with breast cancer risk. A relatively common genotype, combining the two polymorphisms (31I-57V/31I-57V, 3% of controls) was related to a significant 2-fold increase in the risk of post-menopausal breast cancer (OR 1.96; 95% CI 1.01-3.79). No interaction was detected between STK15 variants and estrogenic risk factors, although the power of these analyses was limited. These results suggest that STK15 may represent a low penetrance type breast cancer susceptibility gene. 相似文献
6.
7.
The A2756G polymorphism in the methionine synthase (MTR) gene has been implicated in breast cancer risk. However, the published
findings are inconsistent. We therefore performed a meta-analysis to investigate this relationship. Eleven published case–control
studies, including 8,438 breast cancer cases and 10,515 controls were identified. Odds ratios (ORs) and 95% confidence intervals
(CIs) were used to assess the strength of the association. Overall, no significant associations between the MTR A2756G polymorphism
and breast cancer risk were found for GG versus AA (OR = 0.98, 95% CI: 0.84–1.15), AG versus AA (OR = 0.95, 95% CI: 0.89–1.01),
GG/AG versus AA (OR = 0.95, 95% CI = 0.89–1.01), and GG versus AG/AA (OR = 1.00, 95% CI: 0.86–1.17). However, in the stratified
analysis, significantly decreased breast cancer risks were found among Europeans (AG versus AA, OR = 0.90, 95% CI = 0.83–0.98;
GG/AG versus AA, OR = 0.90, 95% CI = 0.82–0.97) and studies with population-based controls (AG versus AA, OR = 0.93, 95% CI = 0.86–1.00;
GG/AG versus AA, OR = 0.93, 95% CI = 0.86–1.00). When stratifying by the menopausal status, no significant result was observed
in all genetic models. Taken together, the results suggest that the MTR A2756G polymorphism may contribute to susceptibility
to breast cancer among Europeans. 相似文献
8.
Cyclin D1 (CCND1) plays an essential role in tumor development and progression through regulating the cell transition from G1 to the proliferative S phase. The CCND1 G870A polymorphism has been associated with an increased susceptibility to squamous cell carcinoma of the head and neck, bladder, prostate, and gastric cardiac cancers. There are a number of studies that explored the relationship between CCND1 G870A polymorphism and breast cancer risk, with inconsistent conclusions. In order to better define the predictive value of CCND1 G870A polymorphism in breast cancer, we searched PubMed and EBSCO for relevant publications. A total of 13 studies were indentified, which included 11,235 cases and 12,763 controls. We calculated the summary odds ratios and the corresponding 95% confidence interval. Our meta-analysis showed that carriers of AA genotype have a significantly higher risk in developing breast cancer compared with that of GG genotype (OR = 1.08, 95% CI = 1.01-1.17, p > = 0.03) in overall population. Furthermore, in subgroup analysis, CCND1 G870A polymorphism was associated with a marginally increased risk of breast cancer for Chinese compared to Caucasian populations with an OR = 1.14, 95% CI = 1.00-1.20, p-trend = 0.06 for AA + GA versus GG, if the controls were hospital-based population with an OR = 1.21, 95% CI = 0.99-1.47, p = 0.06 for AA versus GG and if the distributions of genotypes in control groups were consistent with the Hardy-Weinberg equilibrium (HWE) with an OR = 1.08, 95% CI = 1.00-1.15, p = 0.04 for AA versus GA + GG. Our meta-analysis represents the largest study to date indicating that the G870A polymorphism in CCND1 confers an increased risk for breast cancer. Further studies are warranted to explore the preventive measures to detect and manage the breast cancers attributable to the G870A polymorphism. 相似文献
9.
Yongsheng Huang Binghui Li Ji Qian Jingtian Xie Long Yu 《Breast cancer research and treatment》2010,123(3):863-868
Transforming growth factor β1 (TGF-β1) is a cytokine, playing an important role in controlling cell proliferation and differentiation
involved in breast cancer. It was reported the 29T/C polymorphism in TGF-β1 has been implicated in breast cancer risk. However,
studies on the association between this polymorphism and breast cancer remain conflicting. To derive a more precise estimation
of the relationship, a meta-analysis of 10,341 cases and 15,655 controls from fifty published case-control studies was performed.
Our analysis suggested that 29T/C has no association with a trend of breast cancer risk when using both dominant [odds ratio
(OR) = 1.01, 95% confidence intervals (CI) 0.96–1.07] and recessive models (OR = 0.98, 95% CI 0.89–1.08) to analyze the data.
In ethnic subgroups analysis, 29T/C also did not appear to be risk factors for breast cancer. However, larger scale primary
studies are required to further evaluate the interaction of TGF-β1 29T/C polymorphism and breast cancer risk in specific populations. 相似文献
10.
Su Lu Zhanwei Wang Dan Cui Hong Liu Xishan Hao 《Breast cancer research and treatment》2011,125(1):253-259
Glutathione S-transferase P1 (GSTP1) is involved in a wide range of detoxifying reactions. Any alteration in the structure,
function, or expression of GSTP1 gene may alter the ability of a cell to inactivate carcinogens or mutagens, and thus modify
an individual’s risk to cancer. Previous epidemiological studies on the potential association between GSTP1 Ile105Val polymorphism
and breast cancer risk have produced inconsistent results. In order to drive a more precise estimation of this association,
we performed a meta-analysis of 30 published case–control studies including 15,901 cases and 18,757 controls. Crude odds ratios
(ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. The results of this meta-analysis
showed that GSTP1 Ile105Val polymorphism was not associated with breast cancer susceptibility in overall population. However,
in subgroup analysis by ethnicity, we found a significant association among Asian population (for Val/Val vs. Ile/Ile: OR
1.27, 95% CI 1.02–1.83; for the recessive model Val/Val vs. Ile/Ile + Ile/Val: OR 1.42, 95% CI 1.20–1.69). When stratified
by study design, significantly elevated susceptibility to breast cancer was found among hospital-based studies (for Val/Val
vs. Ile/Ile: OR 1.38, 95% CI 1.16–1.63; for recessive model Val/Val vs. Ile/Val + Ile/Ile: OR 1.31, 95% CI 1.12–1.55; for
dominant model: Val/Val + Ile/Val vs. Ile/Ile: OR 1.10, 95% CI 1.02–1.19). In conclusion, our meta-analysis suggests that
GSTP1 Ile105Val polymorphism may increase susceptibility to breast cancer in Asian population. 相似文献
11.
Lei Yao Fang Fang Qi Wu Zhen Yang Yang Zhong Long Yu 《Breast cancer research and treatment》2010,122(1):221-227
Breast cancer is one of the most common malignant tumors worldwide. To date, many articles have evaluated the association
between Cytochrome P450c17 (CYP17) T-34C polymorphism and breast cancer risk. However, the results remain inconclusive. In
order to derive a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline,
ISI Web of Knowledge, Cochrane, ScienceDirect, EBSCO, CNKI, and SinoMed databases, 43 studies including 26,008 cases and 32,806
controls were collected for CYP17 T-34C polymorphism. Crude ORs with 95% CIs were used to assess the strength of association
between CYP17 T-34C polymorphism and breast cancer risk. The pooled ORs were performed for codominant model, dominant model,
and recessive model, respectively. Overall, no significant associations between CYP17 T-34C polymorphism and breast cancer
susceptibility were found for TT versus CC (OR = 0.96; 95% CI: 0.89–1.05), TC versus CC (OR = 0.97; 95% CI: 0.89–1.06), TT + TC
versus CC (OR = 0.97; 95% CI: 0.89–1.05) and TT versus TC + CC (OR = 0.98; 95% CI: 0.93–1.03). In the stratified analysis
by ethnicity, menopausal status, and sources of controls, significant associations were still not detected in all genetic
models. In conclusion, this meta-analysis strongly suggests that CYP17 T-34C polymorphism is not associated with breast cancer
risk. 相似文献
12.
Li-Xin Qiu Lei Yao Chen Mao Bo Chen Ping Zhan Hui Yuan Kai Xue Jian Zhang Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):543-547
Published data on the association between MnSOD Val16Ala polymorphism and breast cancer risk are inconclusive. To derive a
more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were
searched. Crude ORs with 95% CIs were used to assess the strength of association between the MnSOD Val16Ala polymorphism and
breast cancer risk. The pooled ORs were performed for co-dominant model (Val/Ala vs. Val/Val, Ala/Ala vs. Val/Val), dominant
model (Ala/Ala + Val/Ala vs. Val/Val), and recessive model (Ala/Ala vs. Val/Ala + Val/Val), respectively. A total of 32 studies
including 26,022 cases and 32,426 controls were involved in this meta-analysis. Overall, no significant associations were
found between MnSOD Val16Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs.
Val/Val: OR = 1.022, 95% CI = 0.981–1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934–1.083; dominant model: OR = 1.013,
95% CI = 0.962–1.066; and recessive model: OR = 0.985, 95% CI = 0.931–1.042). In the subgroup analysis by ethnicity or study
design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests
that the MnSOD Val16Ala polymorphism may be not associated with breast cancer development. However, large sample and representative
population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding. 相似文献
13.
Li-Xin Qiu Hui Yuan Ke-Da Yu Chen Mao Bo Chen Ping Zhan Kai Xue Jian Zhang Xi-Chun Hu 《Breast cancer research and treatment》2010,121(3):703-708
Published data on the association between present/null polymorphism of glutathione S-transferase M1 (GSTM1) and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the GSTM1 present/null polymorphism and breast cancer risk. The pooled ORs were performed for null versus present genotype. A total of 59 studies including 20,993 cases and 25,288 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with null genotype when all studies were pooled into the meta-analysis (OR = 1.10, 95% CI = 1.04–1.16). In the subgroup analysis by ethnicity, significantly increased risks were found for Caucasians (OR = 1.05, 95% CI = 1.00–1.10) and Asians (OR = 1.21, 95% CI = 1.08–1.35). When stratified by population-based studies or hospital-based studies, statistically significantly elevated risks were found among population-based studies (OR = 1.11, 95% CI = 1.03–1.20). In the subgroup analysis by menopausal status, statistically significantly increased risks were found among postmenopausal women (OR = 1.15, 95% CI = 1.04–1.28). In conclusion, this meta-analysis suggests that the GSTM1 null genotype is a low-penetrant risk factor for developing breast cancer. 相似文献
14.
15.
BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects
Li-Xin Qiu Lei Yao Kai Xue Jian Zhang Chen Mao Bo Chen Ping Zhan Hui Yuan Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):487-490
Published data on the association between BRCA2 N372H polymorphism and breast cancer risk are inconclusive. To derive a more
precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength
of association between them. A total of 22 studies including 22,515 cases and 22,388 controls were involved in this meta-analysis.
Overall, no significant associations were found between BRCA2 N372H polymorphism and breast cancer risk when all studies pooled
into the meta-analysis (NH versus NN: OR = 1.01, 95% CI = 0.97–1.05; HH versus NN: OR = 1.05, 95% CI = 0.97–1.13; dominant
model: OR = 1.01, 95% CI = 0.98–1.05; and recessive model: OR = 1.05, 95% CI = 0.98–1.13). In the subgroup analysis by ethnicity,
still no significant associations were found for Caucasians, Asians, or Africans. When stratified by study design, statistically
significantly elevated risk was found for 372H allele based on population-based studies (HH versus NN: OR = 1.11, 95% CI = 1.01–1.21;
dominant model: OR = 1.05, 95% CI = 1.00–1.10; recessive model: OR = 1.09, 95% CI = 1.00–1.18). In conclusion, this meta-analysis
suggests that the BRCA2 372H allele may be a low-penetrant risk factor for developing breast cancer. However, large sample
and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted
to confirm this finding. 相似文献
16.
Nitric oxide (NO) is known to be critically involved in breast carcinogenesis. Genetic polymorphisms of the gene encoding
for endothelial nitric oxide synthase (eNOS), the enzyme catalyzing the production of the NO, are known to predispose to malignant
disease. Increasing evidences showed that eNOS plays a significant role in the development of breast cancer. However, published
data on the association between eNOS 894 G>T polymorphism and breast cancer risk are inconclusive. In order to derive a more
precise estimation of this relationship, a meta-analysis including 11 studies was performed. Crude odds ratios (ORs) with
95% confidence interval (CIs) were used to estimate the strength of the association. The results showed that there was a significant
association with breast cancer risk in TT versus GG (OR = 1.22, 95% CI = 1.02–1.44, P = 0.272) and recessive model TT versus GG/GT (OR = 1.21, 95% CI = 1.02–1.42, P = 0.223). In summary, this meta-analysis primarily suggests that eNOS 894G>T polymorphism is associated with breast cancer. 相似文献
17.
Lei Yao Fang Fang Qi Wu Yang Zhong Long Yu 《Breast cancer research and treatment》2010,122(1):237-242
Breast cancer is the most common cancer in women. To date, many publications have evaluated the association between Cytochrome
P450 1B1 (CYP1B1) Val432Leu polymorphism and breast cancer risk. However, the results remain inconclusive. In order to derive
a more precise estimation of the association, a meta-analysis was performed in this study. By searching Medline, Pubmed, and
ISI Web of Knowledge databases, 26 studies including 19,028 cases and 21,275 controls were collected for CYP1B1 Val432Leu
polymorphism. Crude ORs with 95% CIs were used to assess the strength of association between CYP1B1 Val432Leu polymorphism
and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively.
Overall, no significant associations between CYP1B1 Val432Leu polymorphism and breast cancer susceptibility were found for
Val/Val versus Leu/Leu (OR = 0.98; 95% CI: 0.90–1.06), Val/Leu versus Leu/Leu (OR = 1.01; 95% CI: 0.93–1.09), Val/Val + Val/Leu
versus Leu/Leu (OR = 1.00; 95% CI: 0.93–1.08) and Val/Val versus Val/Leu + Leu/Leu (OR = 0.96; 95% CI: 0.91–1.01). In the
stratified analysis by ethnicity, menopausal status and sources of controls, significant associations were still not observed
in all genetic models. In conclusion, this meta-analysis provides strong evidence that CYP1B1 Val432Leu polymorphism is not
associated with breast cancer risk. 相似文献
18.
Zhanwei Wang Hairong Dong Yuanyuan Fu Haixia Ding 《Breast cancer research and treatment》2010,124(3):765-769
RAD51 plays a key role in homologous recombination repair of double-stranded DNA breaks which may cause chromosomal breaks
and genomic instability. We performed a meta-analysis of 9 epidemiological studies involving 13,241 cases and 13,203 controls
that examined the association between RAD51 135G>C polymorphism and breast cancer. No significant association of RAD51 135G>C
polymorphism with breast cancer was found in overall and European populations. However, after the studies which did not fulfill
Hardy–Weinberg equilibrium were excluded, we observed an overall significant increased breast cancer risk (for the recessive
model CC vs. GG/CG: OR = 1.35, 95% CI = 1.05–1.74, P
heterogeneity = 0.06). In summary, our meta-analysis suggested the RAD51 135G>C polymorphism may contribute to breast cancer susceptibility. 相似文献
19.
Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk 总被引:2,自引:2,他引:0
Langsenlehner U Krippl P Renner W Yazdani-Biuki B Eder T Köppel H Wascher TC Paulweber B Samonigg H 《Breast cancer research and treatment》2005,90(2):113-115
Interleukin-10 (IL-10) is an immunosuppressive cytokine which may facilitate development of cancer by supporting tumor escape from the immune response. A [TCATA] haplotype formed by polymorphisms at positions –3575, –2763, –1082, –819 and –592 in the promoter of the IL-10 gene is a strong determinant for IL-10 expression. The presence of this haplotype can be determined by analysis of the –592C > A polymorphism. Aim of the present study was to analyze the role of the IL-10 [TCATA] haplotype for breast cancer. We performed a case–control study including 500 female patients with histologically confirmed breast cancer and 500 female, age-matched, healthy control subjects from population-based screening studies. The –592C > A polymorphism was determined by a 5-nuclease assay (TaqMan). Frequency of the homozygous –592 AA genotype, indicating homozygosity for the [TCATA] haplotype, was 4.2% among patients and 7.3% among controls (p=0.038; odds ratio 0.56; 95% confidence interval 0.32–0.97). IL-10 genotypes were not associated with tumor size, histological grading, estrogen or progesterone receptor status and age at diagnosis. Therefore we conclude that the IL-10 –592C > A promoter polymorphism may be associated with a reduced breast cancer risk. 相似文献
20.
Jian Zhang Li-Xin Qiu Zhong-Hua Wang Xiang-Hua Wu Xiao-Jian Liu Bi-Yun Wang Xi-Chun Hu 《Breast cancer research and treatment》2010,123(2):549-555
Published data on the association between MTHFR C677T polymorphism and breast cancer risk are inconclusive. To derive a more
precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched.
Crude ORs with 95% CIs were used to assess the strength of association between the MTHFR C677T polymorphism and breast cancer
risk. The pooled ORs were performed with co-dominant model (CT vs. CC, TT vs. CC), dominant model (CT + TT vs. CC), and recessive
model (TT vs. CC + CT), respectively. A total of 37 studies including 15,260 cases and 20,411 controls were involved in this
meta-analysis. Overall, significantly elevated breast cancer risk was associated with TT variant genotype in homozygote comparison
and dominant genetic model when all studies were pooled into the meta-analysis (TT vs. CC: OR = 1.11, 95% CI = 1.01–1.23;
dominant model: OR = 1.04, 95% CI = 1.00–1.09). In the subgroup analysis by ethnicity, significantly increased risks were
found for TT allele carriers among Asians (TT vs. CC: OR = 1.18, 95% CI = 1.04–1.35; recessive model: OR = 1.15, 95% CI = 1.03–1.29).
When stratified by study design, statistically significantly elevated risk was found in hospital-based studies (TT vs. CC:
OR = 1.18, 95% CI = 1.02–1.38; recessive model: OR = 1.17, 95% CI = 1.05–1.29). In the subgroup analysis by menopausal status,
statistically significantly increased risk was found among postmenopausal women (CT vs. CC: OR = 1.12, 95% CI = 1.02–1.23;
dominant model: OR = 1.11, 95% CI = 1.01–1.22). In conclusion, this meta-analysis suggests that the MTHFR T allele is a low-penetrant
risk factor for developing breast cancer. 相似文献